Lutèo Medical
Microbiome-powered therapeutic options for dermatology.
The founders
The company
Lutèo Medical is a University of Manchester spinout developing microbiome-based dermatology products for chronic inflammatory skin conditions, a large market in which many patients rely on steroids and immunomodulators that manage symptoms rather than underlying microbial drivers.
Who else is building in this space
Companies working on the same thing, at every stage.
Scale-up
Clinical-stage biotechnology company developing IL-1beta-targeted therapies for immune-mediated inflammatory diseases
Unicorn
Develops engineered antibodies with extended half-lives to provide high-potency monotherapies and rational combinations for inflammatory bowel disease
Unicorn
Developing next-generation small molecule protein degraders to treat cancer and beyond
Scale-up
Developer of endolysin-based targeted antibacterial products
Harnessing bacterial communities derived directly from the human gastrointestinal tract to prevent and treat diseases
Clinical stage specialty biopharmaceutical company
Thousands more founded every month.
Dealroom tracks new companies as they appear — founders, funding and signals, over the API or in the platform.